Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Valdecoxib (SC 65872) is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 59.00 | |
10 mg | In stock | $ 90.00 | |
25 mg | In stock | $ 196.00 | |
50 mg | In stock | $ 360.00 | |
100 mg | In stock | $ 535.00 | |
500 mg | In stock | $ 1,190.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 54.00 |
Description | Valdecoxib (SC 65872) is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications. |
Targets&IC50 | COX-2:5 nM |
In vitro | Valdecoxib demonstrates significant efficacy in acute and chronic inflammation models in rats, with ED50 values of 0.06 mg/kg for carrageenan air-pouch inflammation, 5.9 mg/kg for paw edema, and 0.03 mg/kg for nonspecific arthritis. When administered alone, valdecoxib shows slow absorption in vivo, achieving a maximum inhibition of 16% in edema at 3 hours post-administration. In contrast, the valdecoxib complexes VALD-βCd and VALD-SBE7βCd exhibit high absorption rates, suppressing over 50% of edema within 1 hour, and achieving a maximum inhibition of 66% at 3 hours. Orally administered valdecoxib inhibits carrageenan-induced rat paw edema with an ED50 value of 10.2 mg/kg. In a rat model of nonspecific arthritis, oral valdecoxib shows chronic anti-inflammatory activity, with an ED50 of 0.032 mg/kg/day. Valdecoxib also inhibits prostaglandin production at the inflammation site in rats with carrageenan air-pouch inflammation when administered orally, with an ED50 value of 0.02 mg/kg. |
In vivo | Valdecoxib inhibits the production of PGE2 in plasma induced by lipopolysaccharides (IC50: 0.89 μM) and suppresses the generation of TxB2 in plasma (IC50: 25.4 μM). It binds to COX-2 with a Ka of 1.1×10^5 M/s and exhibits a strong overall saturable binding affinity to COX-2 of 2.6 nM. After 15 minutes (DP15), valdecoxib has a solubility percentage of 10.5%, while its hydrophilic derivatives (VALD-βCd, VALD-HPβCd, and VALD-SBE7βCd complexes) display significantly increased solubility percentages of 50%, 91%, and 93%, respectively. |
Synonyms | SC 65872 |
Molecular Weight | 314.36 |
Formula | C16H14N2O3S |
CAS No. | 181695-72-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31.4 mg/mL (100 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Valdecoxib 181695-72-7 Immunology/Inflammation Neuroscience COX Inhibitor inhibit SC-65872 Cyclooxygenase SC65872 SC 65872 inhibitor